About the
cGvHD Project
This Action has brought together chronic GvHD (cGvHD) researchers across Europe for the first time, creating a network of cross-disciplinary experts in the field.
Our COST Action EUROGRAFT linked research groups, clinical teams and industry partners throughout Europe. This enabled a breakthrough in scientific developments, leading to new concepts for improving the survival and quality of life of transplant patients.
The Action also permitted to improve current understanding of the pathogenesis of cGvHD and its associated co-morbidities.
We developed a coordinated approach to therapy, thus strengthening European research and innovation via collaboration.
The outputs and resources generated during our Action are publicly available via our website
What is the project about?
Chronic GvHD (cGvHD) is a multi-organ allo and autoimmune disorder and a major cause of non-relapse morbidity and mortality following allogeneic haematopoietic stem cell transplantation (HSCT).
It occurs in an estimated 50% of patients following allo-HSCT and causes a plethora of co-morbidities. Until now, there was a lack of coordination at the European research level into cGVHD diagnosis and therapy. We built up this Action to improve patient care through an harmonization of the treatment approaches across transplant centres.
Key Facts
Chronic GvHD (cGvHD) is a multi-organ allo and auto immune disorder and a major cause of non-relapse morbidity and mortality following allogeneic haematopoietic stem cell transplantation (HSCT).
Chronic GvHD (cGvHD) occurs in an estimated 50% of patients following allo-HSCT and causes a plethora of co-morbidities.
This COST Action has offered a platform for industry and clinical teams, early career investigators and highly experienced researchers from cross-disciplines, including bioinformatics, immunology, epidemiology, genetics and cell biology, to enable the dissemination of integrated clinical and laboratory information via established and improved databases. Adding this to large-scale populations studies, we helped to further understand the pathogenesis of cGvHD, empowering a personalised medicine approach to improve patient outcomes.
By studying large-scale populations, the Actio enabled us to understand the pathogenesis of cGvHD and develop a coordinated approach to therapy.
Are you interested
in taking part?
If you would like to join the network, have a general query or any suggestion, please connect with us.
Do you have a question?
If you have any questions or would like to know more about the project, simply connect with us and we’ll be happy to talk to you.
